Laboratory Tests

Samples were analyzed by the National Center for Drug Analysis for compliance with the specifications in the official compendial monographs (except sterility requirements). Initial analyses were performed by methods deemed appropriate by NCDA. Check analyses, as required, were made by the official method. Testing was performed on each of six sub-samples from each batch.

Summary of Results

Of the 51 samples of these drugs that were analyzed (see Table 1) two samples of Progesterone Injection, one labeled 25.0 mg/ml and the other labeled 50.0 mg/ml were found defective due to substrength.